Comparison of contrast-induced nephrotoxicity of iodixanol and iopromide in patients with renal insufficiency undergoing coronary angiography

American Journal of Cardiology

Volumn 108, Issue 2, 2011, Pages 189-194

  Shin, Dong Ho ^a   Choi, Dong Ju ^b   Youn, Tae Jin ^b   Yoon, Chang Hwan ^b   Suh, Jung Won ^b   Kim, Kwang Il ^b   Cho, Young Seok ^b   Cho, Goo Yeong ^b   Chae, In Ho ^b   Kim, Cheol Ho ^b  

^a Yonsei University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IODIXANOL; IOPROMIDE; NICORANDIL; NITRATE; URIC ACID;

ADULT; AGE; AGED; ANEMIA; ANGIOCARDIOGRAPHY; AORTA BALLOON; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; CONTRAST ENHANCEMENT; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HEART EJECTION FRACTION; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCORING SYSTEM;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CREATININE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IOHEXOL; KIDNEY DISEASES; MALE; RENAL INSUFFICIENCY; TRIIODOBENZOIC ACIDS;

EID: 79959712003     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2011.03.019     Document Type: Article

References (23)

1. C. Briguori, F. Airoldi, D. D'Andrea, E. Bonizzoni, N. Morici, A. Focaccio, I. Michev, M. Montorfano, M. Carlino, J. Cosgrave, B. Ricciardelli, and A. Colombo Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies Circulation 115 2007 1211 1217 (Pubitemid 46594764)
2. R. Mehran, E.D. Aymong, E. Nikolsky, Z. Lasic, I. Iakovou, M. Fahy, G.S. Mintz, A.J. Lansky, J.W. Moses, G.W. Stone, M.B. Leon, and G. Dangas A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation J Am Coll Cardiol 44 2004 1393 1399 (Pubitemid 39303939)
3. R. Mehran, and E. Nikolsky Contrast-induced nephropathy: definition, epidemiology, and patients at risk Kidney Int Suppl 2006 S11 S15
4. S.-H. Jo, T.-J. Youn, B.-K. Koo, J.-S. Park, H.-J. Kang, Y.-S. Cho, W.-Y. Chung, G.-W. Joo, I.-H. Chae, D.-J. Choi, B.-H. Oh, M.-M. Lee, Y.-B. Park, and H.-S. Kim Renal toxicity evaluation and comparison between Visipaque (iodixanol) and Hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial J Am Coll Cardiol 48 2006 924 930 (Pubitemid 44308573)
5. P. Aspelin, P. Aubry, S.-G. Fransson, R. Strasser, R. Willenbrock, and K.J. Berg Nephrotoxic effects in high-risk patients undergoing angiography N Engl J Med 348 2003 491 499 (Pubitemid 36159884)
6. R.J. Solomon, M.K. Natarajan, S. Doucet, S.K. Sharma, C.S. Staniloae, R.E. Katholi, J.L. Gelormini, M. Labinaz, and A.E. Moreyra Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease Circulation 115 2007 3189 3196 (Pubitemid 47012233)
7. W. Laskey, P. Aspelin, C. Davidson, M. Rudnick, P. Aubry, S. Kumar, F. Gietzen, M. Wiemer, and D.S. Group Nephrotoxicity of iodixanol versus iopamidol in patients with chronic kidney disease and diabetes mellitus undergoing coronary angiographic procedures Am Heart J 158 2009 822 828
8. M.R. Rudnick, C. Davidson, W. Laskey, J.L. Stafford, and P.F. Sherwin Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) trial Am Heart J 156 2008 776 782
9. R. Wessely, T. Koppara, C. Bradaric, M. Vorpahl, S. Braun, S. Schulz, J. Mehilli, A. Schmig, and A. Kastrati Choice of contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention Circ Cardiovasc Interv 2 2009 430 437
10. P.A. McCullough, M.E. Bertrand, J.A. Brinker, and F. Stacul A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media J Am Coll Cardiol 48 2006 692 699 (Pubitemid 44175706)
11. R. Solomon The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients Kidney Int 68 2005 2256 2263 (Pubitemid 43117802)
12. M.C. Heinrich, L. Hberle, V. Mller, W. Bautz, and M. Uder Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials Radiology 250 2009 68 86
13. M. Reed, P. Meier, U.U. Tamhane, K.B. Welch, M. Moscucci, and H.S. Gurm The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials JACC Cardiovasc Interv 2 2009 645 654
14. B. Nie, W.-J. Cheng, Y.-F. Li, Z. Cao, Q. Yang, Y.-X. Zhao, Y.-H. Guo, and Y.-J. Zhou A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention Catheter Cardiovasc Interv 72 2008 958 965
15. C.P. Juergens, J.P. Winter, P. Nguyen-Do, S. Lo, J.K. French, H. Hallani, C. Fernandes, N. Jepson, and D.Y.C. Leung Nephrotoxic effects of iodixanol and iopromide in patients with abnormal renal function receiving N-acetylcysteine and hydration before coronary angiography and intervention: a randomized trial Int Med J 39 2009 25 31
16. United States FoodDrug Administration Berlex voluntarily recalls Ultravist injection 370 mgI/mL http://www.fda.gov/Safety/Recalls/ArchiveRecalls/ 2006/ucm112020.htm Accessed on April 5, 2011
17. H.S. Thomsen, S.K. Morcos, and B.J. Barrett Contrast-induced nephropathy: the wheel has turned 360 degrees Acta Radiol 49 2008 646 657
18. A. Caixeta, and R. Mehran Evidence-based management of patients undergoing PCI: contrast-induced acute kidney injury Catheter Cardiovasc Interv 75 suppl 2010 S15 S20
19. K.A. Sterling, T. Tehrani, and M.R. Rudnick Clinical significance and preventive strategies for contrast-induced nephropathy Curr Opin Nephrol Hypertens 17 2008 616 623
20. C. Briguori, A. Colombo, F. Airoldi, N. Morici, G.M. Sangiorgi, A. Violante, A. Focaccio, M. Montorfano, M. Carlino, G. Condorelli, and B. Ricciardelli Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine Kidney Int 68 2005 2250 2255 (Pubitemid 43117801)
21. R. Solomon, G. Deray CIN CPf How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations Kidney Int Suppl 2006 S51 S53
22. G.J. Merten, W.P. Burgess, L.V. Gray, J.H. Holleman, T.S. Roush, G.J. Kowalchuk, R.M. Bersin, A. Van Moore, C.A. Simonton, R.A. Rittase, H.J. Norton, and T.P. Kennedy Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial JAMA 291 2004 2328 2334 (Pubitemid 38656299)
23. I. Goldenberg, and S. Matetzky Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies CMAJ 172 2005 1461 1471 (Pubitemid 40803495)